Speaker

Steven Rowe, MD

EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER, CYSTIC FIBROSIS FOUNDATION
Bethesda, Maryland, United States
Steven M. Rowe, MD, has served as the executive vice president and chief scientific officer of the Cystic Fibrosis Foundation since April 2022. He oversees the Foundation’s basic science, academic research, and venture philanthropy program investments, which include the CF Foundation Lab and the Foundation’s Path to a Cure initiative to develop treatments for all people with cystic fibrosis.

Dr. Rowe’s life’s work has been dedicated to treating people with CF and researching treatments to improve their lives. Prior to his role at the CF Foundation, he served as the CF Research Center Director at the University of Alabama at Birmingham while treating people with CF as a trained pulmonologist. Dr. Rowe is board-certified in Internal Medicine, Pediatrics, Pulmonary Medicine, and Critical Care Medicine.

Dr. Rowe is an accomplished academic physician-scientist, a pioneer in personalized therapeutics for CF, cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and he has made critical advances in interpreting function in the genetic cause of CF to foster therapeutic development.

Dr. Rowe has a remarkable ability to identify, establish, and cultivate effective collaborations across institutional and geographic boundaries to address important problems in respiratory and genetic diseases. He has over 220 peer-reviewed publications and published in multiple prestigious medical journals, including the New England Journal of Medicine, Nature, Science, and Science Translational Medicine.

* To advance drug development and a search for a cure, the Cystic Fibrosis Foundation (CFF) has contracts with several companies to help fund the development of potential treatments and/or cures for cystic fibrosis. Pursuant to these contracts, CFF may receive milestone-based payments, equity interests, royalties on the net sales of therapies, and/or other forms of consideration. Resulting revenue received by CFF is used in support of our mission. See “How Drugs Get on the Pipeline” on the CFF website for more: https://www.cff.org/Our-Research/Drug-Development-Pipeline-101/How-Drugs-Get-on-the-Pipeline/.
Speaking In
3:30 PM - 4:30 PM
Monday, June 5
How can patient advocacy groups attract an early-stage company to develop technology for their…